Healthcare Security And Privacy Are To Be Of Prime Concern In The Us Polycystic Ovarian Syndrome Treatment Market

Prevalence of endocrine diseases in the US is on a rise as the country's urban residents continue to bear the brunt of their sedentary lifestyles. Rising incidence of endometriosis, unexplained infertility and polycystic ovarian syndrome (PCOS) continues to alarm public health authorities across the US.

Measures undertaken by non-profit organizations and US health regulatory bodies are promoting the awareness of PCOS treatments. Also, therapies for diseases associated with PCOS are being developed to bear out the unmet clinical needs of people suffering from such complications.

Get Going With Sample Of US Polycystic Ovarian Syndrome Treatment Market Report! https://www.persistencemarketresearch.com/samples/14317

Company Profiles

Sanofi
Novartis AG
Teva Pharmaceutical Industries Limited
Merck KGaA
AstraZeneca
How About Re-Inventing The Methodical Wheel In The US Polycystic Ovarian Syndrome Treatment Market? Switch Over To The "Methodology" Tab! https://www.persistencemarketresearch.com/methodology/14317

Despite this, the demand for PCOS treatment continues to incur a sluggish growth across the US. Persistence Market Research's recent publication estimates that the US$ 230 Mn PCOS treatment market in the US will exhibit a moderate value CAGR of 3.9% to reach US$ 313.2 Mn by the end of 2024.

The foremost growth inhibitor for polycystic syndrome treatment market in the US is pending approval of drugs at the FDA. The US FDA continues to prolong the approval for drugs on polycystic syndrome treatment. And, this has severely lowered the production of effective medicines, thereby impacting the adoption of PCOS treatment.

Presently, no drugs have been approved by the FDA for direct treatment of PCOS. Physicians are thus providing drug prescriptions through off-label indications, which is incidentally diverting patients to generic drugs.

Titled as "Polycystic Syndrome Treatment Market: US Industry Analysis and Forecast, 2016-2024," the report projects that in 2016, more than US$ 66 Mn worth of oral contraceptive drugs were consumed in the US polycystic syndrome treatment market.

Keeping A Tab On Key Players In The US Polycystic Ovarian Syndrome Treatment Market? Go To "Purchase Now" To Decipher The Competitive Analysis In Our US Polycystic Ovarian Syndrome Treatment Market Report! https://www.persistencemarketresearch.com/checkout/14317

Through 2024, oral contraceptives will be exhibiting a steady revenue growth at 5.3% CAGR, and will account for nearly one-third share of market value. Besides, the demand for insulin sensitizing agents is expected to close in on number of oral contraceptives consumed in the US PCOS treatment market during this forecast period. Furthermore, growing preference to advanced drugs will also boost the consumption of aromatase inhibitors & SERMs, revenues from which will reach US$ 49 Mn by 2024-end.

More than 47% of US polycystic syndrome treatment market will be accounted by drug sales through hospital pharmacies. With hospitals as the largest distribution channel, nearly US$ 150 Mn worth of PCOS drugs will be sold through these pharmacies.

Meanwhile, PCOS drug sales through e-commerce platforms are projected to showcase a value CAGR of 4.6%, higher than that of hospital pharmacies and other distribution channels such as fertility clinics, drug stores and over-the-top counters.

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.